Megasoft [MEGASOFT] vs Kilitch Drugs [KILITCH] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Megasoft Ltd. wins in 12 metrics, Kilitch Drugs (India) Ltd. wins in 6 metrics, with 0 ties. Megasoft Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Megasoft Ltd. | Kilitch Drugs (India) Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 7.91 | 20.30 | Megasoft Ltd. |
| Price-to-Book Ratio | 4.71 | 1.98 | Kilitch Drugs (India) Ltd. |
| Debt-to-Equity Ratio | 1.39 | 31.65 | Megasoft Ltd. |
| PEG Ratio | -0.07 | -0.31 | Megasoft Ltd. |
| EV/EBITDA | 8.20 | 18.54 | Megasoft Ltd. |
| Profit Margin (TTM) | 80.76% | 12.76% | Megasoft Ltd. |
| Operating Margin (TTM) | -1,366.82% | 9.69% | Kilitch Drugs (India) Ltd. |
| EBITDA Margin (TTM) | N/A | 9.69% | N/A |
| Return on Equity | 64.13% | 13.32% | Megasoft Ltd. |
| Return on Assets (TTM) | 26.26% | 8.54% | Megasoft Ltd. |
| Free Cash Flow (TTM) | $194.75M | $-293.31M | Megasoft Ltd. |
| 1-Year Return | 406.26% | -15.49% | Megasoft Ltd. |
| Price-to-Sales Ratio (TTM) | 195.06 | 2.69 | Kilitch Drugs (India) Ltd. |
| Enterprise Value | $11.98B | $5.34B | Megasoft Ltd. |
| EV/Revenue Ratio | 7.02 | 2.58 | Kilitch Drugs (India) Ltd. |
| Gross Profit Margin (TTM) | 67.21% | 42.60% | Megasoft Ltd. |
| Revenue per Share (TTM) | $23 | $62 | Kilitch Drugs (India) Ltd. |
| Earnings per Share (Diluted) | $23.90 | $7.85 | Megasoft Ltd. |
| Beta (Stock Volatility) | 0.94 | 0.03 | Kilitch Drugs (India) Ltd. |
Megasoft Ltd. vs Kilitch Drugs (India) Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Megasoft Ltd. | 4.73% | 10.55% | 44.16% | 161.67% | 113.81% | 115.74% |
| Kilitch Drugs (India) Ltd. | -3.33% | -1.11% | 16.16% | 12.55% | 3.84% | -0.60% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Megasoft Ltd. | 406.26% | 1,175.68% | 3,858.99% | 4,620.00% | 1,731.82% | 249.37% |
| Kilitch Drugs (India) Ltd. | -15.49% | 72.82% | 131.81% | 1,009.43% | 521.22% | 188.64% |
Performance & Financial Health Analysis: Megasoft Ltd. vs Kilitch Drugs (India) Ltd.
| Metric | MEGASOFT | KILITCH |
|---|---|---|
| Market Information | ||
| Market Cap | ₹301.22B | ₹5.57B |
| Market Cap Category | Large cap | Small cap |
| 10 Day Avg. Volume | 98,661 | 113,561 |
| 90 Day Avg. Volume | 157,453 | 69,256 |
| Last Close | ₹435.80 | ₹172.66 |
| 52 Week Range | ₹79.50 - ₹446.00 | ₹117.25 - ₹250.00 |
| % from 52W High | -2.29% | -30.94% |
| All-Time High | ₹446.00 (Jun 01, 2026) | ₹500.00 (Jul 15, 2025) |
| % from All-Time High | -2.29% | -65.47% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | -0.04% |
| Quarterly Earnings Growth | N/A | -0.26% |
| Financial Health | ||
| Profit Margin (TTM) | 0.81% | 0.13% |
| Operating Margin (TTM) | -13.67% | 0.10% |
| Return on Equity (TTM) | 0.64% | 0.13% |
| Debt to Equity (MRQ) | 1.39 | 31.65 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹40.12 | ₹80.61 |
| Cash per Share (MRQ) | ₹18.13 | ₹24.88 |
| Operating Cash Flow (TTM) | ₹-2,034,262,016 | ₹8.18M |
| Levered Free Cash Flow (TTM) | ₹165.06M | ₹267.01M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Megasoft Ltd. vs Kilitch Drugs (India) Ltd.
| Metric | MEGASOFT (Apr 11, 2026) | KILITCH (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 7.91 | 20.30 |
| Forward P/E | N/A | 10.42 |
| PEG Ratio | -0.07 | -0.31 |
| Price to Sales (TTM) | 195.06 | 2.69 |
| Price to Book (MRQ) | 4.71 | 1.98 |
| Market Capitalization | ||
| Market Capitalization | ₹301.22B | ₹5.57B |
| Enterprise Value | ₹11.98B | ₹5.34B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.02 | 2.58 |
| Enterprise to EBITDA | 8.20 | 18.54 |
| Risk & Other Metrics | ||
| Beta | 0.94 | 0.03 |
| Book Value per Share (MRQ) | ₹40.12 | ₹80.61 |
Financial Statements Comparison: Megasoft Ltd. vs Kilitch Drugs (India) Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | MEGASOFT (2025) | KILITCH (2025) |
|---|---|---|
| Revenue/Sales | 0 | 1.97B |
| Cost of Goods Sold | 0 | 1.07B |
| COGS % of Revenue | - | 54.1% |
| Gross Profit | 0 | 904.87M |
| Gross Margin | - | 45.9% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | -145.21M | 286.34M |
| Operating Margin | - | 14.5% |
| EBITDA | 311.05M | 386.66M |
| EBITDA Margin | - | 19.6% |
| Pre-Tax Income | 84.47M | 344.74M |
| Pre-Tax Income % of Revenue | - | 17.5% |
| Income Tax | 0 | 95.34M |
| Income Tax % of Revenue | - | 4.8% |
| Net Income (Profit) | -299.37M | 249.40M |
| Profit Margin | - | 12.6% |
Balance Sheet & Liquidity Metrics
| Metric | MEGASOFT (2025) | KILITCH (2025) |
|---|---|---|
| Cash & Equivalents | 91.70M | 97.49M |
| Total Current Assets | 560.34M | 1.74B |
| Total Current Assets % of Revenue | - | 88.2% |
| Total Current Liabilities | 683.12M | 843.10M |
| Total Current Liabilities % of Revenue | - | 42.7% |
| Long-Term Debt | 1.30B | 277.70M |
| Long-Term Debt % of Revenue | - | 14.1% |
| Total Shareholders Equity | 1.44B | 2.00B |
| Retained Earnings | 348.54M | 1.11B |
| Retained Earnings % of Revenue | - | 56.2% |
| Property, Plant & Equipment | 2.00B | 41.13M |
Cash Flow Statement Comparison
| Metric | MEGASOFT (2025) | KILITCH (2025) |
|---|---|---|
| Operating Cash Flow | -492.05M | 8.18M |
| Operating Cash Flow % of Revenue | - | 0.4% |
| Capital Expenditures | -172.66M | N/A |
| Free Cash Flow | 194.75M | -293.31M |
| FCF Margin | - | -14.9% |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MEGASOFT | KILITCH |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 1.76B | 34.96M |
| Float Shares | 20.43M | 9.61M |
| % Held by Insiders | 17.06% | 72.22% |
| % Held by Institutions | 0.00% | 0.00% |
| % Held by Public | 82.94% | 27.78% |
Dividend Analysis & Yield Comparison: Megasoft Ltd. vs Kilitch Drugs (India) Ltd.
| Metric | MEGASOFT | KILITCH |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | ₹0.00 | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |